ASML’s China Risk Is Expected, But the Market Hasn’t Priced in the Downside

The market's 97% surge in ASML's stock over the past six months wasn't a single event. It was a sustained reaction to a powerful beat-and-raise cycle, where each quarterly print consistently outpaced the whisper number and management's guidance reset the trajectory higher. The fourth quarter of 2025 was the latest, and most decisive, leg of that climb.

The numbers were a clear beat. For the quarter, ASML reported total net sales of €9.7 billion, edging past the consensus estimate of €9.6 billion. But the real surprise was in the forward-looking metric of demand. The company's net bookings came in at 13.2 billion euros, a staggering figure that crushed the analyst estimate of €6.32 billion. This wasn't just a beat; it was a record quarter for orders, signaling a major step-up in customer capacity plans driven by AI demand. The market was not fully pricing in this acceleration.

Management's guidance for 2026 cemented the new, higher path. The company set its full-year sales target between €34 billion and €39 billion. This range is notably above the prior year's full-year 2025 sales of €32.7 billion, representing a clear growth mandate. The mid-point of this guidance also sits above the analyst consensus of €35.1 billion, indicating management is setting its own, more optimistic benchmark. This forward view reset expectations, turning a strong quarter into a multi-year growth story.

The stock's persistent buying interest, culminating in that 97% surge, shows the market was not fully pricing in this acceleration. The beat-and-raise cycle created a powerful feedback loop: strong results fueled optimism, which drove the price higher, which in turn lowered the bar for future performance. The key question now is whether the market has priced in the full potential of that 2026 growth path-or if the next beat could still be a surprise.

The New Baseline: Priced-In Growth and the 2026 Guide

The market has now absorbed the 2026 guide. The stock's recent trajectory suggests the significant step-up in growth is essentially priced in. Management's forecast for 2026 total net sales between €34 billion and €39 billion implies a year-over-year increase of 10% to 20% from the prior year's €32.7 billion. That's a meaningful acceleration from the 15% growth seen in 2025, but the market's reaction has been muted. The current price target of $1,438.75 implies virtually no upside from recent levels, indicating the guide has been fully discounted.

This creates a new baseline. The expectation gap has narrowed. The stock's 97% surge over six months was fueled by the surprise in Q4 bookings and the initial guide. Now, that guide is the new reality. The forward view has reset, and the market is waiting for execution. The key question shifts from "Will they grow?" to "Can they hit the high end of that range?" Any stumble in converting the massive backlog or a miss on the top end of the sales target could reset expectations downward.

The company's capital return plan adds another layer. The €12 billion share buyback program announced alongside the guide provides a floor of support. However, its impact is diluted over three years, with the program extending to the end of 2028. This means the buyback's earnings-per-share boost will be spread thin, acting more as a long-term commitment than a near-term catalyst. It signals confidence but doesn't alter the near-term growth narrative priced into the stock.

The bottom line is that the easy money has been made. The beat-and-raise cycle has run its course, and the 2026 guide is now the priced-in story. For the stock to move materially higher, the company must not just meet, but exceed, the high end of that guidance range. Any deviation from that path will be scrutinized against the new, elevated baseline.

The China Risk: A Specific, Expected Headwind

While the market has priced in robust global growth, a specific and quantified risk remains: the impact of U.S. export restrictions on China. Management has explicitly flagged this as a headwind to the 2026 guide. The company stated it does not expect 2026 total net sales to be below 2025, a cautious baseline that implies a significant decline in its China business. Given that China sales were a meaningful part of the €32.7 billion total in 2025, a major drop there would require outsized growth elsewhere to hit the €34-39 billion target. This is the expectation gap the market must now watch.

The scale of the financial commitment amplifies this risk. The announced share buyback program of up to €12 billion is a major use of cash, with execution stretching to the end of 2028. This capital return plan reduces the financial flexibility available to absorb a sharper-than-expected China sales decline. If the China headwind materializes more severely than anticipated, the company's ability to fund the buyback or invest in other areas could be constrained, creating a tension between shareholder returns and operational resilience.

This risk is magnified by the stock's valuation. ASML currently scores just 1 out of 6 on Simply Wall St's valuation checks, with a DCF model suggesting the share price trades around 78% above its intrinsic value. Such a rich valuation leaves the stock highly sensitive to any shift in growth or margin assumptions. A China-related sales miss, even if it doesn't derail the full-year guide, could quickly reset the market's view of the company's long-term cash flow trajectory, pressuring the premium.

The bottom line is that the China risk is not a vague fear but a specific, expected subtraction from the 2026 sales target. The market has priced in the guide, but not necessarily the downside scenario. With the buyback program committing significant capital and the valuation already stretched, any deviation from the optimistic path will be scrutinized. The stock's high score on the valuation risk scale means the expectation gap here is not about growth, but about the stability of that growth.

The Verdict: Is It Too Late?

The investment case now hinges on a narrow expectation gap. The market has priced in a successful 2026, leaving little room for error. The primary catalyst is the upcoming Q1 2026 results, due in April. Management has set a clear guide for the quarter: total net sales between €8.2 billion and €8.9 billion. Any miss on that target would be a sharp signal that the 2026 growth path is stalling, triggering a re-rating downward.

The expectation gap has narrowed significantly. The stock's 97% surge over six months was fueled by the surprise in Q4 bookings and the initial guide. Now, that guide is the priced-in story. The current analyst price target of $1,438.75 implies virtually no upside, confirming the market has absorbed the optimistic trajectory. The forward view has reset, and the stock is now priced for flawless execution.

The answer hinges on two specific risks. First, the severity of the China headwind. The company's cautious baseline-that 2026 sales won't fall below 2025-implies a major decline in that business. If the actual sales drop is sharper than feared, it could pressure margins and strain the financial flexibility needed to fund the new €12 billion share buyback program. Second, execution on the 2026 guide must be flawless. With the stock trading at a rich valuation-around 78% above its intrinsic value in a DCF model-the market has no patience for stumbles.

In short, the easy money has been made. The beat-and-raise cycle has run its course. For the stock to move materially higher from here, ASML must not just meet, but exceed, the high end of its own 2026 guide. Any deviation from that path, especially on the China front, will be scrutinized against the new, elevated baseline. The verdict is that it may be too late for a simple continuation of the rally; the stock now needs to deliver on its own ambitious promises.